Target intelligence / Profile preview

JUN divergent transcript (JUN-DT)

Target
JUN-DT
Molecular classification
Long noncoding RNA (lncRNA), Noncoding transcript
01

Overview

JUN divergent transcript (JUN-DT), also annotated as LOC101926907, is a human long noncoding RNA (lncRNA) gene transcribed in a region adjacent to the protein-coding JUN gene. The term "divergent transcript" refers to a genomic organization where transcription occurs in the opposite direction to a nearby protein-coding gene, often resulting in noncoding RNAs known as promoter upstream transcripts (PROMPTs) or upstream antisense RNAs (uaRNAs)[1]. Most divergent lncRNAs, including JUN-DT, are considered non-functional or of unknown function, but some can regulate gene expression locally through chromatin modifications or transcriptional interference. Currently, there is no evidence that JUN-DT encodes a protein or functions as a receptor, enzyme, or classical pharmacological target, nor are there established drugs or therapies that act upon this transcript[4][1]. If you require structured data for integration, this information can be directly mapped to fields in a bioinformatics or pharmacological database, but it should be noted that JUN-DT is not an active target in drug discovery or established therapeutic paradigms.

Other names
LOC101926907JUN-DTJUN divergent transcript
02

Biological functions

Transcriptional regulation (by association, as divergent lncRNAs can modulate nearby gene expression, including transcription factor JUN/AP-1)Possible involvement in gene origination and chromatin modulation (postulated for divergent transcripts and lncRNAs in general)
03

Disease associations

There are no established, direct disease roles for JUN-DT. The broader category of divergent lncRNAs has been implicated in processes such as cancer and cell differentiation, but specific disease associations for JUN-DT are not described in available referenced sources[1][4].

Beyond the preview

Go deeper on JUN divergent transcript (JUN-DT).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on JUN divergent transcript (JUN-DT).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call